The US Food and Drug Administration (FDA) granted accelerated approval for sotorasib in 2021 and adagrasib in 2022 for the treatment of previously treated patients with advanced NSCLC harboring KRAS G12C mutations based on these studies. This evidence concerns the gene KRAS and non-small cell lung carcinoma.